In the Press

IMRIC's Dr. Yehudit Bergman: Studying The Outside Influences On Genes

Dr. Yehudit Bergman

Hebrew U. cancer researcher looks at how cells adapt to their environment.

Canada’s Governor General On Upcoming Visit To Israel, Partnerships, and Innovation

The flags of Canada and Israel

Canada’s Governor General On Upcoming Visit To Israel: Canada And Israel Can Forge New Partnerships In Innovation - Let’s continue to collaborate and to strengthen our innovation ecosystem.

Hebrew University Finds New Immunity Approach

Hebrew University Finds New Immunity Approach

Prof. Raymond Kaempfer and colleagues have produced what is described as “landmark” research paper.

IMRIC’S Yuval Dor One Of Four Recipients Of Merck $1 Million Grant For Multiple Sclerosis Innovation

IMRIC’S Yuval Dor One Of Four Recipients Of Merck $1 Million Grant For Multiple Sclerosis Innovation

Merck, a leading science and technology company, announced recipients of the fourth annual Grant for Multiple Sclerosis Innovation (GMSI) during a symposium at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London. This year, 260 proposals from 45 countries were submitted, representing innovative research projects taking place across the globe. Four research teams from the United Kingdom, Spain, Canada, Israel, Germany and Qatar were selected to share in the €1 million grant to support their research.

RenewSense Enters Brainnovation, Israel's Brain Technologies Accelerator

Prof. Amir Amedi
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that RenewSense was selected to enter Brainnovation, Israel's Brain Technologies accelerator.

BioBlast Jumps On Muscular Dystrophy Drug Results

CEO Colin Foster

NOTE: Dr. Haya Lorberboum-Galski, Chairperson of The Institute for Medical Research Israel-Canada (IMRIC) at The Hebrew University of Jerusalem, was a key member of the research team behind this work.

Globes header - Bioblast

The Israeli drug developer sees potential initial sales of over $1 billion for Cabaletta, which could be marketed by 2017.

BioBlast CEO Colin FosterBioBlast Pharma Ltd.(Nasdaq:ORPN) announced promising interim results on Tuesday from its Phase II study of its leading treatment, Cabaletta, with 25 patients suffering from oculopharyngeal muscular dystrophy (OPMD). Due to the success of the open label HOPEMD trial, the Israeli drug developer seeks to fast track a Phase III study in 2016.

Cabaletta showed statistically significant improvements for patients in several tests, while also hitting its marks for safety and tolerability. The study was conducted at two research centers -- Hadassah-Hebrew University Medical Center in Jerusalem and Montreal Neurological Institute at McGill University in Canada.

“The interim results for OPMD, specifically with respect to dysphagia and muscle strength and function, give us insight into the potential of Cabaletta for use in other protein aggregation-related diseases, such as spinocerebellar ataxia type 3 (SCA3 or Machado Joseph disease), another devastating hereditary disease in which we are planning a pivotal Phase 3 study in the US and EU,” said CEO Colin Foster.

There is currently no approved treatment for OPMD, a rare muscle-wasting disease characterized by swallowing difficulties. "There is a critical unmet need for patients with this rare disorder,” said Peter L. Saltonstall, the leader of the National Organization for Rare Disorders. "We are grateful to BioBlast and to the physicians and patients who have committed their time and resources to this important clinical trial."

BioBlast believes it may be able to get the treatment on the market by 2017, with initial sales potential of more than $1 billion. In pre-market trading on Nasdaq, BioBlast share price was up by over 20%.

HUJI Professor At IMRIC Honoured With Helmholtz International Fellow Award For Epigenetics Research

Helmholtz Award Ceremony honouring Yehudit Bergman

The Israeli immunologist and cancer researcher Professor Yehudit Bergman of the Hebrew University of Jerusalem (HUJI), Israel, has been honored with the Helmholtz International Fellow Award for her excellent research. In a prize ceremony at the MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin, Germany, MDC's interim director Professor Thomas Sommer presented the certificate to her on Thursday, June 18th, 2015.

National Geographic Daily News: App Helps the Blind "See" With Their Ears


New technology allows people to perceive color and shape through music.

redOrbit Article On IMRIC Research: "Colors And Shapes Can Be Heard By The Blind: Study"

colours and shapes
See video

Normally, people perceive colors and shapes visually, but what if you could “hear” them? A new study from Hebrew University shows that using sensory substitution devices (SSDs), colors and shapes can now be conveyed to the brain noninvasively through other senses.

Medical Xpress Article On IMRIC Research: "New Treatment Proposed To Prevent Devastating Intestinal Inflammation In Cancer Patients"

Naama Kanarek

Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation – has been achieved by an international team of researchers from the US and Israel headed by scientists at the Hebrew University of Jerusalem.